Sarepta Therapeutics (SRPT) Assets Average (2011 - 2026)

Sarepta Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $3.3 billion for Q1 2026.

• In Q1 2026, Assets Average fell 12.11% year-over-year to $3.3 billion; the TTM figure through Mar 2026 stood at $3.3 billion (down 12.11% YoY), while the FY2025 annual figure was $3.7 billion, up 1.18% from the prior year.
• Assets Average was $3.3 billion for Q1 2026 at Sarepta Therapeutics, down from $3.4 billion in the prior quarter.
• In the past five years, Assets Average ranged from a high of $3.8 billion in Q4 2024 to a low of $3.0 billion in Q2 2022.
• Historically, Assets Average has averaged $3.3 billion across 5 years, with a median of $3.2 billion in 2024.
• The sharpest annual moves came in 2024 and 2026: Assets Average advanced 18.65% in 2024, then decreased 12.11% in 2026.
• A 5-year view of Assets Average shows it stood at $3.1 billion in 2022, then rose by 1.43% to $3.2 billion in 2023, then rose by 18.65% to $3.8 billion in 2024, then decreased by 9.52% to $3.4 billion in 2025, then declined by 4.6% to $3.3 billion in 2026.
• The last three Assets Average figures came in at $3.3 billion (Q1 2026), $3.4 billion (Q4 2025), and $3.6 billion (Q3 2025), per Business Quant data.